Orchard Therapeutics is a publicly traded, commercial-stage biotechnology company pioneering innovative gene therapies for rare diseases. We've demonstrated sustained clinical benefit in over 150 patients across five disease areas, leveraging our autologous ex vivo gene therapy platform. Our portfolio includes Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA, and several other programs in advanced clinical trials. We collaborate with leading academic institutions globally, bringing together the best minds in gene therapy research and development. Orchard operates in a dynamic and fast-paced environment. Our tech stack includes technologies such as Amazon Web Services (including CloudFront and the Virginia region), Ruby on Rails, and Envoy, showcasing our commitment to leveraging cutting-edge technology to advance our mission. We prioritize a collaborative and results-oriented engineering culture fostering innovation and efficient execution. We are dedicated to transforming the lives of patients with rare diseases and building a company culture of passion, collaboration, and integrity. This commitment extends to our employees, who are key to our success. Our current team of 101-250 employees enjoys a supportive and engaging work environment focused on making a meaningful difference in the lives of others. Orchard Therapeutics has received significant funding, including over $494 million in funding rounds and continues to grow and expand its clinical pipeline. This commitment to innovation positions us for continued growth and leadership in the field of gene therapy.